Exploring the Continual Progression & Efforts to Target RAS

Time: 9:00 am
day: Day One


  • Discuss the clinical value for KRAS mutant cancers through targeting the specific isoform G12C
  • Highlight the importance of targeting other alleles such as G12D
  • Emphasise the feedback responses gained from Inhibiting RAS and the targeting potential for future therapies